Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 27, 2006Diabetes Care

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPablo AschnerPontificia Universidad JaverianaMKMark KipnesDiabetes & Glandular Disease ClinicJLJared LuncefordDecision Sciences (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aschner et al. (2006) studied this question.

synapsesocial.com/papers/6a7d08a1ade38b7dc346c9behttps://doi.org/10.2337/dc06-0703
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum1993 · 1,170 citations
  2. 2Basal and dynamic proinsulin-insulin relationship to assess β-cell function during OGTT in metabolic disorders2003 · 42 citations
  3. 3GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes2004 · 228 citations